D.E. Shaw & Co’s Beta Bionics BBNX Stock Holding History

D.E. Shaw & Co’s Portfolio BBNX Stock Details BBNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-13,142	Closed	-$400K	–	5177
2025 Q4	$400K	Buy	+13,142	New	+$351K	﹤0.01%	4026

Other funds holding BBNX

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

D.E. Shaw & Co's BBNX Position: Q1 2026 in Review

D.E. Shaw & Co sold out of Beta Bionics (BBNX) in Q1 2026, closing a stake of 13,142 shares — an estimated $400K sold.

D.E. Shaw & Co first reported a position in BBNX in Q4 2025 and held it in 1 quarter. The position peaked at $400K in Q4 2025. 130 funds tracked by Wall St. Rank hold BBNX as of Q1 2026.

D.E. Shaw & Co reported no remaining Beta Bionics position as of Q1 2026 after selling out during the quarter.
D.E. Shaw & Co sold 13,142 Beta Bionics shares in Q1 2026, an estimated $400K.
D.E. Shaw & Co first reported a position in Beta Bionics in Q4 2025 and held it in 1 quarter.
D.E. Shaw & Co's Beta Bionics position peaked at $400K in Q4 2025.
130 funds tracked by Wall St. Rank held Beta Bionics as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.